Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) Sees Significant Decline in Short Interest

Posted by Paula Ricardo on Mar 24th, 2026

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA – Get Free Report) was the recipient of a significant decline in short interest during the month of March. As of March 13th, there was short interest totaling 449 shares, a decline of 87.7% from the February 26th total of 3,660 shares. Currently, 0.2% of the shares of the stock are sold short. Based on an average trading volume of 3,086 shares, the short-interest ratio is currently 0.1 days. Based on an average trading volume of 3,086 shares, the short-interest ratio is currently 0.1 days. Currently, 0.2% of the shares of the stock are sold short.

Bitwise MARA Option Income Strategy ETF Trading Down 6.3%

IMRA stock traded down $0.89 during midday trading on Tuesday, reaching $13.17. The stock had a trading volume of 13,032 shares, compared to its average volume of 5,949. Bitwise MARA Option Income Strategy ETF has a 52-week low of $11.99 and a 52-week high of $60.73. The company’s fifty day simple moving average is $14.66 and its 200 day simple moving average is $22.87. The company has a market cap of $3.16 million, a price-to-earnings ratio of 263.40 and a beta of -6.67.

Insider Activity at Bitwise MARA Option Income Strategy ETF

In related news, insider Helen Louise Collins sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $27.76, for a total transaction of $138,800.00. Following the completion of the sale, the insider directly owned 25,000 shares in the company, valued at approximately $694,000. The trade was a 16.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 37.30% of the company’s stock.

About Bitwise MARA Option Income Strategy ETF

(Get Free Report)

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.